TROG 07.04 - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Registration Link

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

TROG 08.01 – PROFIT

TROG 07.03 – RadioHUM

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000